Cost-effectiveness of felodipine-metoprolol (Logimax®) and enalapril in the treatment of hypertension

Clinical and Experimental Hypertension

Volumn 20, Issue 8, 1998, Pages 833-846

  Andersson, Fredrik ^a   Kartman, Bernt ^b   Andersson, Ove K ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost effectiveness; Enalapril; Felodipine; Hypertension; Logimax ; Metoprolol

Indexed keywords

ENALAPRIL; FELODIPINE PLUS METOPROLOL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SWEDEN;

EID: 0031763198     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969809053250     Document Type: Article

References (16)

1. Shulman, S.R., Lasagna, L., editors. Pricing and reimbursement of pharmaceuticals: an evaluation of cost-containment strategies. PharmacoEconomics 1994; 6 Suppl 1: 1-87.
2. Johannesson, M., Jönsson B. A review of cost-effectiveness analyses of hypertension treatment. PharmacoEconomics 1992; 1: 250-264.
3. Hosie, J., Wiklund, I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9: S15-S18.
4. Ménard, J., Chatellier, G. Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens 1995; 9: S19-S23.
5. Hansson, L., Zanchetti, A. The Hypertension Optimal Treatment (HOT) Study - patient characteristics: randomization risk profiles, and early blood pressure results. Blood Pressure 1994; 3: 322-327.
6. Astra AB. A report from the Hypertension Optimal Treatment (HOT) Study Satellite Symposium to the Eighth European Meeting on Hypertension, Milan, Italy, 17 June 1997.
7. Andersson, O.K. for the Swedish multicentre group. More effective blood pressure control with once daily felodipine-metoprolol (Logimax®) than with enalapril (Abstract). Am J Hypertens 1995; 8: 189A.
8. Drummond, M.F., Stoddart, G.L., Torrance G.W. Methods for the economic evaluation of health care programmes, Oxford University Press, Oxford, 1990.
9. Smart, A.J., Walters, L. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors. S Afr Med J 1994; 84: 834-837.
10. Schrott, H.G., Stein, E.A, Dujovne, C.A., Davidson, M.H., Goris, G.B., Oliphant, T.H., Phillips., J.C., Shawaryn., G.G. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995; 75: 34-39.
11. Laska, E.M., Meisner, M., Siegel, C. The usefulness of average cost-effective ratios. Health Economics 1997; 6: 497-504.
12. LINFO, Läkemedelsinformation AB, Pharmacevtiska specialiteter i Sverige 1997 (FASS 97) (in Swedish), LINFO, Läkemedelsinformation AB, Stockholm, 1997.
13. Johannesson, M., Borgquist, L., Elenstål, A., Jönsson, B., Tilling, B. Hypertonibehandling vid en vårdcentral 1: Männens läkemedel mycket dyrare an kvinnornas (in Swedish). Läkartidningen 1991; 88: 1096-1098.
14. Isles, G.G., Walker, L.M., Beevers, G.D., Brown, I., Cameron, H.L., Clarke, J. Hawthorne, V., Hole, D., Lever, A.F., Robertson, J.W.K., Wapshaw, J.A. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4: 141-156.
15. Kannel, W.B., Wolf, P.A., Garrison, R.J., editors. The Framingham Study: an epidemiological investigation of cardiovascular disease, Section 34, Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements, 30 year follow up, US Department of Commerce, National Technical Information Service, Springfield, 1987.
16. Johannesson, M., Jönsson, B. Cost-effectiveness analysis of hypertension treatment - a review of methodological issues. Health Policy 1991; 19: 55-78.